Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2025
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended March 31, 

($ in thousands)

    

2025

    

2024

EmrosiTM

​

$

2,070

​

$

—

Qbrexza®

​

​

5,161

​

​

5,017

Accutane®

​

 

3,655

​

 

5,819

Amzeeq®

​

​

1,100

​

​

755

Zilxi®

​

​

426

​

​

273

Other / legacy

​

​

727

​

​

1,166

Total product revenues

​

$

13,139

​

$

13,030